Top Markets
#1 AI XOVIA AI XOVIA +34.12%
#2 Zora Zora +23.98%
#3 Seeker Seeker +22.89%
#4 Full Moon Full Moon +18.71%
#5 Axelar Axelar +15.12%
#6 rsERG rsERG +14.92%
#7 Ergo Ergo +13.46%
#8 0G 0G +10.86%
#9 Notcoin Notcoin +10.67%
#10 VVS Finance VVS Finance +10.62%
Coin of the day
AI XOVIA AI XOVIA
Settings
Language
ENGLISH
Currency
USD
Theme
Eikon Therapeutics, Inc. Common Stock Eikon Therapeutics, Inc. Common Stock

Eikon Therapeutics, Inc. Common Stock

EIKN
Rank in Stocks #12317
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established... Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Share Price
$11.03
Last synced: 2026-08-28
Market Cap
$597.15M
Change (1 day)
-4.25%
Change (1 year)
-
Country
US
Trade Eikon Therapeutics, Inc. Common Stock (EIKN)

Category

Healthcare
P/E ratio for Eikon Therapeutics, Inc. Common Stock (EIKN)
P/E ratio as of 2026 TTM: 0
According to Eikon Therapeutics, Inc. Common Stock latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Eikon Therapeutics, Inc. Common Stock from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.